Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
05 oct. 2023 08h00 HE
|
Paratek Pharmaceuticals
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies...
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
21 sept. 2023 08h58 HE
|
Paratek Pharmaceuticals
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek...
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
18 sept. 2023 09h37 HE
|
Paratek Pharmaceuticals
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
12 sept. 2023 07h30 HE
|
Paratek Pharmaceuticals
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
03 août 2023 08h00 HE
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point...
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings
02 août 2023 17h36 HE
|
Paratek Pharmaceuticals
Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on...
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
10 juil. 2023 08h00 HE
|
Paratek Pharmaceuticals
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE...
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
27 juin 2023 12h01 HE
|
Paratek Pharmaceuticals
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
27 juin 2023 08h00 HE
|
Paratek Pharmaceuticals
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023
12 juin 2023 08h00 HE
|
Paratek Pharmaceuticals
BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...